[1]王威巍,张宇,尤楠,等.粪便细菌移植对肝性脑病大鼠肝功能及血氨的影响[J].第三军医大学学报,2017,39(13):1321-1326.
 WANG Weiwei,ZHANG Yu,YOU Nan,et al.Effects of fecal microbiota transplantation on liver function and blood ammonia in hepatic encephalopathy rats[J].J Third Mil Med Univ,2017,39(13):1321-1326.
点击复制

粪便细菌移植对肝性脑病大鼠肝功能及血氨的影响(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
39卷
期数:
2017年第13期
页码:
1321-1326
栏目:
基础医学
出版日期:
2017-07-15

文章信息/Info

Title:
Effects of fecal microbiota transplantation on liver function and blood ammonia in hepatic encephalopathy rats
作者:
王威巍张宇尤楠郑璐李靖
第三军医大学新桥医院肝胆外科
Author(s):
WANG Weiwei ZHANG Yu YOU Nan ZHENG Lu LI Jing

Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

关键词:
粪便细菌移植肝性脑病肝功能血氨大鼠
Keywords:
fecal microbiota transplantation hepatic encephalopathy liver function blood ammonia rats
分类号:
R333.4; R378.2; R575.3
文献标志码:
A
摘要:

目的         建立大鼠肝性脑病及FMT细菌模型,确定粪便细菌移植对肝性脑病大鼠肝功能及血氨的影响,初步了解粪便细菌移植(fecal microbiota transplantation, FMT)的临床意义。方法         选择32只SD大鼠,采用CCL4+酒精的方法建立大鼠肝性脑病模型及肠道埋管,分为4组(A组:正常对照组;B组:肝性脑病模型组;C组:益生菌组;D组:FMT组),对C组进行益生菌移植,200 μL/d (200 μL益生菌溶液中含益生菌2.7×109),持续2周;对D组进行FMT移植,200 μL/d (200 μL粪便细菌溶液中含粪便细菌2.7×109),持续2周。记录大鼠一般生存情况及大便情况,对移植前后体重进行比较,测定移植前、后肝功能(ALT、AST、ALB、TB及DB)和门静脉及尾静脉血氨。结果        所有实验大鼠均未出现死亡;粪便细菌移植后肝性脑病大鼠体重移植前明显增加[D组移植前(225.18±14.81) g,移植后2周(266.83±33.40)g,P<0.05];移植后大鼠肝功能较前明显好转[移植后2周ALT:D组与B组分别为(610.49±4.98)U/L和(990.07±4.80)U/L,P<0.05;AST:D组与B组分别为(72.46±4.42)U/L和(101.58±2.19)U/L,P<0.05;ALB:D组与B组比较ALB明显上升,分别为(24.48±0.12)g/L和(17.53±0.53)g/L,P<0.05;TB:D组为(13.45±0.77)μmol/L,B组为(27.20±0.77)μmol/L,P<0.05;DB:D组为(10.04±0.09)μmol/L,B组为(16.04±0.51)μmol/L,P<0.05];门静脉及尾静脉血氨较移植前明显降低[D组门静脉及尾静脉血氨分别为(26.26±0.30)μmol/L和(23.10±0.35)μmol/L,B组分别为(36.28±1.32)μmol/L和(32.90±0.35)μmol/L,P<0.05]。结论        对大鼠进行人体粪便细菌移植是可行的;粪便细菌移植可改善肝性脑病大鼠的肝功能,降低血氨。

Abstract:

Objective         To establish a rat model of hepatic encephalopathy (HE) and fecal microbiota transplantation (FMT), investigate the effects of FMT on liver function and blood ammonia in order to explore the clinical significance of FMT. Methods         Totally 32 rats were divided into 4 groups with 8 animals in each group, that is, normal control group, HE group, probiotics group, and FMT group. The SD rats model of HE was established through CCL4+ alcohol injection, and the intestinal pipe was buried. The rats of the probiotics group were given probiotics transplantation (200 μL/d, containing probiotics of 2.7×109), and those of the FMT group were given FMT (200 μL/d, containing fecal microbiota of 2.7×109). After 2 weeks’ treatment, the survival, defecation, and body weight, liver function (ALT, AST, ALB, TB and DB) and blood ammonia of portal vein and caudal vein before and after transplantation were recorded and compared. Results       No death was observed in all experimental rats. When compared with the indexes before transplantation, FMT resulted in obvious increase in the body weight (266.83±33.40 vs 225.18±14.81 g, P<0.05), significantly improved liver function (FMT group vs HE group, ALT: 610.49±4.98 vs 990.07±4.80 U/L, P<0.05; AST: 72.46±4.42 vs 101.58±2.19 U/L, P<0.05; ALB: 24.48±0.12 vs 17.53±0.53 g/L, P<0.05; TB: 13.45±0.77 vs 27.20±0.77 μmol/L, P<0.05; DB: 10.04±0.09 vs 16.04±0.51 μmol/L, P<0.05). The ammonia contents in the portal and tail venous blood were significantly decreased in the rats after than before FMT treatment (26.26±0.30 and 23.10±0.35 μmol/L respectively in the portal and tail venous blood in the FMT group, and 36.28±1.32 and 32.90±0.35 μmol/L in the HE group, P<0.05). Conclusion        Human fecal bacteria transplantation is feasible in rats. FMT treatment can improve liver function and reduce the blood ammonia in HE rats.

参考文献/References:

[1]American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[J]. J Hepatol,2014,61(3):642-659. DOI:10.1016/j.jhep.2014.05.042.
[2]PATIDAR K R, BAJAJ J S. Antibiotics for the treatment of hepatic encephalopathy[J]. Metab Brain Dis, 2013, 28(2): 307-312. DOI:10.1007/s11011-013-9383-5.
[3]HUANG E, ESRAILIAN E, SPIEGEL B M R. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy-a decision analysis[J]. Alimentary Pharmacology & Therapeutics, 2007, 26(8): 1147-1161. DOI:10.1111/j.13652036.2007.03464.x.
[4]BERG A M, FARRAYE F A. Duodenal infusion of stool is more effective than vancomycin in patients with recurrent Clostridium difficile[J]. Evid Based Med, 2013, 18(6): 220-221. DOI:10.1136/eb-2013-101308.
[5]SATOKARI R, MATTILA E, KAINULAINEN V, et al. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection—an observational cohort study[J]. Aliment Pharmacol Ther, 2015, 41(1): 46-53. DOI:10.1111/apt.13009.
[6]HAMILTON M J, WEINGARDEN A R, SADOWSKY M J, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection[J]. Am J Gastroenterol, 2012, 107(5): 761-767. DOI:10.1038/ajg.2011.482.
[7]DAI C, GUANDALINI S, ZHAO D H, et al. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function[J]. Mol Cell Biochem, 2012, 362(1-2): 43-53. DOI:10.1007/s11010-011-1126-5.
[8]中华医学会消化病学分会,中华医学会肝病学分会. 中国肝性脑病诊治共识意见(2013 )[J]. 中国医学前沿杂志(电子版), 2014, 6(2):81-93. DOI:10.3760/cma.j.issn.0254-1432.2013.09.002.
Digestive Disease Association of Chinese Medical Association, Liver Disease Association of Chinese Medical Association. Chinese consensus on the medical diagnosis and treatment of hepatic encephalopathy(2013)[J]. Chin J Front Med Sci(Elect Ver), 2014, 6(2):81-93. DOI:10.3760/cma.j.issn.0254-1432.2013.09.002.
[9]PETROF E O, KHORUTS A. From stool transplants to next-generation microbiota therapeutics[J]. Gastroenterology, 2014, 146(6): 1573-1582. DOI:10.1053/j.gastro.2014.01.004.
[10]VRIEZE A, VAN NOOD E, HOLLEMAN F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J]. Gastroenterology, 2012, 143(4): 913-916. DOI:10.1053/j.gastro.2012.06.031.
[11]KAO D, ROACH B, PARK H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy[J]. Hepatology, 2016, 63(1): 339-340. DOI:10.1002/hep.28121.
[12]FARJAM M, DEHDAB P, ABBASSNIA F, et al. Thioacetamideinduced acute hepatic encephalopathy in rat: behavioral, biochemical and histological changes.[J]. Iranian Red Crescent medical journal, 2012(3): 164-170.
[13]PLANER J D, PENG Y, KAU A L, et al. Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice[J]. Nature, 2016, 534(7606): 263-266. DOI:10.1038/nature17940.
[14]RIDAURA V K, FAITH J J, REY F E, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice[J]. Science, 2013, 341(6150): 1241214. DOI:10.1126/science.1241214.

相似文献/References:

[1]王海英,吕宪民,曹亦宾,等.急性重症脑卒中并肝性脑病误诊2例[J].第三军医大学学报,2010,32(07):703.
[2]卿轶,董志.当归多糖对大鼠肝性脑病的预防作用[J].第三军医大学学报,2008,30(23):2187.
 QING Yi,DONG Zhi.Angelica sinensis polysaccharides prevents rat from hepatic encephalopathy[J].J Third Mil Med Univ,2008,30(13):2187.
[3]胡扬腾,于世远,张殿玉,等.33例肝性脑病酸碱失衡的分析[J].第三军医大学学报,1985,07(03):0.[doi:10.16016/j.1000-5404.1985.03.011 ]
 Hu Yangteng,Yu Shiyuan,Zhang Dianyu.[J].J Third Mil Med Univ,1985,07(13):0.[doi:10.16016/j.1000-5404.1985.03.011 ]
[4]何振平,刘永雄.闭塞分流口治愈预防性脾脏分流术后肝性脑病一例[J].第三军医大学学报,1982,04(03):0.[doi:10.16016/j.1000-5404.1982.03.016 ]

更新日期/Last Update: 2017-07-11